8 completed, 1 terminated, 1 withdrawn. 10 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Terminated 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
Follow rasagiline: new trials by email Literature Review of rasagiline trials Research Report on rasagiline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease Rasagiline - REM Sleep Behavior Disorder, Parkinson Disease | Phase 2 / Phase 3 | Withdrawn | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2023-01-01 | 2025-01-07 | |
| Image Parkinson's Disease Progression Study Rasagiline, Placebo, Magnetic Resonance Imaging - Parkinson's Disease | Phase 2 | Completed | University of Florida | 96 | 2016-12-01 | 2023-09-06 |
| Rasagiline Rescue in Alzheimer's Disease Clinical Trial Rasagiline, Placebo - Alzheimer's Disease | Phase 2 | Completed | The Cleveland Clinic | 50 | 2015-05-01 | 2020-11-10 |
| Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),, Placebo, P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), - Parkinson's Disease | Phase 2 / Phase 3 | Completed | Pharma Two B Ltd. | 149 | 2013-12-01 | 2023-04-07 |
| Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS) Rasagiline, Placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Completed | Richard Barohn, MD | 80 | 2013-11-21 | 2020-01-27 |
| Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis Rasagiline, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | University of Ulm | 252 | 2013-06-01 | 2016-10-25 |
| Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) rasagiline - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Completed | Yunxia Wang, MD | 36 | 2011-12-01 | 2018-05-18 |
| Safety and Efficacy of Rasagiline in Restless Legs Syndrome rasagiline, placebo (sugar pill) - Restless Legs Syndrome | Phase 2 / Phase 3 | Terminated | University of Virginia | 52 | 2010-09-01 | 2013-02-11 |
| Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) rasagiline mesylate, placebo - Multiple System Atrophy | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 174 | 2009-12-01 | 2015-02-26 |
| Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) Rasagiline - Dementia, Alzheimer's Disease | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 376 | 2004-08-01 | 2009-07-15 |
Amyotrophic Lateral Sclerosis (3) · Parkinson Disease (3) · Alzheimer Disease (2) · Dementia (1) · Multiple System Atrophy (1) · REM Sleep Behavior Disorder (1) · Restless Legs Syndrome (1) · Synucleinopathies (1)
Teva Branded Pharmaceutical Products R&D, Inc. (2) · Pharma Two B Ltd. (1) · Richard Barohn, MD (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · The Cleveland Clinic (1) · University of Florida (1) · University of Ulm (1) · University of Virginia (1) · Yunxia Wang, MD (1)
United States (8) · Canada (3) · Germany (2) · Israel (2) · Australia (1) · Austria (1) · France (1) · Hungary (1) · Italy (1) · Netherlands (1) · Portugal (1) · South Africa (1) · Spain (1) · United Kingdom (1)
Albert C. Ludolph, MD, Prof. (1) · Baorong Zhang, MD (1) · Bernad Ravina, MD. MSCE (1) · David E Vaillancourt, PhD. (1) · Jeffrey L Cummings, MD, ScD (1) · Richard Barohn, MD (1) · Tiffini S Voss, MD (1) · Timothy Hsu (1) · Werner Poewe, Prof (1) · Yunxia Wang, MD (1)
PMID 25498732, PMID 29934198, PMID 37975796
2009 (1), R01NS052318 (1)